8日上午，中共中央、国务院在人民大会堂举行2015年度国家科学技术奖励大会。大会共评选出295个获奖项目和7名外籍科技专家。其中康缘药业承担的“以桂枝茯苓胶囊为示范的现代中药功效相关质量标准体系创立及应用”项目荣获国家科技进步奖二等奖。这是康缘药业第二次获得国家科技进步奖二等奖。
On the morning of August 8, the CPC Central Committee and the State Council held the 2015 National Science and technology award conference in the Great Hall of the people. 295 award-winning projects and 7 foreign science and technology experts were selected. Among them, Kangyuan Pharmaceutical Co., Ltd. won the second prize of national science and Technology Progress Award for the project of "establishment and application of quality standard system related to efficacy of modern Chinese medicine with Guizhi Fuling Capsule as the demonstration". This is the second time that Kangyuan pharmaceutical won the second prize of national science and technology progress award.
据了解，目前，我国中药标准现状与国际药品标准水平存在较大差距。这主要是因为中成药标准落后，普遍存在指标成分少、与功效关联性不强的问题，难以保障药品的安全、有效。与此同时，中成药质量可控性差，执行的是“合格”标准，没有质量一致性的“高”要求，产品批次间质量差异大，难以保障质量均一和疗效稳定。这些都严重阻碍了中药现代化、国际化进程。
It is understood that at present, there is a big gap between the current situation of Chinese traditional medicine standards and the international drug standards. This is mainly because the standard of Chinese patent medicine is backward, and there are many problems, such as less index components and weak correlation with efficacy, which are difficult to ensure the safety and effectiveness of drugs. At the same time, the quality controllability of Chinese patent medicine is poor, the "qualified" standard is implemented, there is no "high" requirement of quality consistency, the quality difference between batches of products is large, and it is difficult to guarantee the quality uniformity and the curative effect stability. All these have seriously hindered the modernization and internationalization of traditional Chinese medicine.